For the first quarter of 2010, the company posted a EBITDA of $298m, compared to loss of $201m for the prior year period. Profit after tax (PAT) was $210m, compared to loss of $153m for the year ago period. Operational PAT, excluding forex translations, was $143m, compared to loss of $5m for the prior year period.

Atul Sobti, CEO and managing director of Ranbaxy, said: “Solid growth in key geographies, along with optimal delivery value from First-to-File opportunities in the USA, ensured that we achieved yet another quarter of strong operational performance. We also launched Project Viraat, a comprehensive program aimed at India leadership, in January, 2010.”

Will Ranbaxy continue at same pace in Q2?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.